(Worthy News) – All 18 COVID-19 patients hospitalized with moderate or severe symptoms who received the drug Amor-18 developed by Israeli biotech company Amorphical recovered and were discharged in a few days, the company announced on Wednesday. Of the 19 individuals who were given a placebo, six had to be transferred to intensive care, and two died.
As part of compassionate care, two other patients in a very serious condition were given the drug. Both recovered and were discharged.
“Since the patients treated with the drug recovered within a few days and were released to their home, this was 100% successful,” said Dr. Nashat Abu Saleh, co-director of the coronavirus department at Ziv Medical Center in Safed, where the phase II clinical trial was conducted. [ Source: Jerusalem Post (Read More…) ]
We're being CENSORED ... HELP get the WORD OUT! SHARE!!!
Fair Use Notice:This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material from this site for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.